ProCE Banner Activity

Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HER2-Negative Metastatic Breast Cancer

Conference Coverage
Slideset

Initial results suggest that patritumab deruxtecan is active across a broad range of HER3 expression levels in patients with heavily pretreated HER2-negative MBC.

Released: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.